Systematic review reveals HER2-targeted PET/CT effectively identifies HER2-positive lesions in breast cancer, suggesting clinical implications.
Highlights HER2-targeted PET/CT showed moderate to good lesion-level concordance with biopsy Both mAb-and affinity protein-based tracers identified HER2-positive lesions Most false-positive lesions were HER2-low, not HER2-zero Selective verification limited specificity and false-negative assessment Standardized, therapy-linked studies are needed to define clinical utility HER2-Targeted PET/CT in Breast Cancer: A Systematic Review of Lesion-Level Concordance with Pathology
No takes yet. Share an insight, caveat, or question.
Burén et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: